Pill Version of Wegovy Is Approved for Use in the U.S.
PositiveFinancial Markets

- Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) for the oral version of its weight-loss medication, Wegovy, which is set to be available for purchase at a cash price of $149 per month starting in early 2026. This marks a significant milestone as it is the first GLP-1 medication to be offered in pill form.
- The approval is crucial for Novo Nordisk as it aims to expand its market presence in the weight management sector, following the success of its injectable versions of semaglutide, marketed as Ozempic and Wegovy.
- However, the company faces challenges as recent trials of semaglutide for Alzheimer's treatment have failed, leading to a decline in its stock value. This juxtaposition highlights the volatility in the pharmaceutical market, where advancements in one area can be overshadowed by setbacks in another.
— via World Pulse Now AI Editorial System

